Source comparison
Ipamorelin Safe Side Effects: Clinical Trial Data Versus Real-World Observations
Injection Site Reactions 6–8% mild erythema, resolved <60 min 12–15% when using rapid injection technique Normal immune response—slow injection to 30 sec reduces incidence by ~40% Transient Fatigue 4–6% subjects, dose-dependent 8–10% with morning dosing, <2% w
This comparison does not assign a generated winner or score.
- Injection Site Reactions
- 6–8% mild erythema, resolved <60 min
- 12–15% when using rapid injection technique
- Normal immune response—slow injection to 30 sec reduces incidence by ~40%
- Transient Fatigue
- 4–6% subjects, dose-dependent
- 8–10% with morning dosing, <2% with evening protocols
- Timing-dependent—evening administration eliminates most cases
- Headache
- <3% in controlled settings
- 5–7% in unmonitored use
- Almost always dehydration or electrolyte shift—increase water intake 500+ mL on dose days
- Flushing/Vasodilation
- 2–4% subjects, transient
- 4–6% depending on injection site
- Confirms bioactivity—not a safety concern unless persistent >2 hours
- Nausea
- <2% at therapeutic doses
- 3–5% at doses >400 mcg
- Dose-dependent—keep dosing ≤300 mcg to minimise incidence
- Cortisol Elevation
- 0% (no statistically significant change)
- Undetectable in properly dosed protocols
- Key safety differentiator vs older secretagogues like GHRP-2